Vitamin D3 and the Stress-axis in MS

Regulation of the Stress-axis by Vitamin D3 in Subjects With Multiple Sclerosis; a Double-blinded, Randomized, Placebo-controlled Study

Patients with multiple sclerosis (MS) have an increased risk of developing a major depression. The investigators observed a protective effect of high vitamin D levels on the risk of depression in MS. This might be driven by the effect of vitamin D on the stress-axis. Therefore, the main goal of the present study is to assess whether high dose vitamin D supplementation results in a suppression of the stress-axis, as measured by decreased levels of cortisol.

Study Overview

• Status: Terminated
• Conditions: Multiple Sclerosis
• Intervention / Treatment: Other: Placebo comparator; Drug: Cholecalciferol

Detailed Description

The lifetime incidence of a major depression in Multiple Sclerosis (MS) is 50%. (Patten et al. Neurology 2003; 61(11):1524-7) Our group reported a negative correlation between vitamin D status and depression score of the Hospital Anxiety and Depression Scale (HADS) in a cross-sectional dataset of Dutch MS patients. (Knippenberg et al. Acta Neurol Scand 2011; 124(3):171-5) This suggests an interaction between vitamin D and biological mechanisms affecting susceptibility to depression. Currently, we have two main hypotheses: 1) Vitamin D regulates the hypothalamic stress axis in MS. Based on our findings that cortisol releasing hormone (CRH)-positive hypothalamic neurons in the brains of MS patients stained positive for the vitamin D receptor (VDR) and 1,25(OH)2D-24-hydroxylase (24-OHase). (smolders et al. J Neuropathol Exp Neurol 2013;72(2):91-105) 2) Vitamin D affects T cell cytokine profile and hereby the odds of developing depression. Also in non-MS depressed patients increased levels of pro-inflammatory cytokines are detected (Maes et al. Metab Brain Dis 2009; 24: 27-53). Vitamin D3 has shown to be a potent promotor of T cell regulation both in vitro and in vivo. (Smolders et al. J Neuroimmunol 2008;194:7-17 and Smolders et al. PLoS One 2010;5:e15235) The main goal of this study is to assess whether supplementation of high doses vitamin D3 results in a suppression of saliva cortisol day-curves in subjects with multiple sclerosis, and we will explore whether the pro-inflammatory cytokine profile of T lymphocytes is regulated.

• Study Type: Interventional
• Enrollment (Actual): 54
• Phase: Phase 2

Contacts and Locations

Study Locations

• Netherlands
  • Nijmegen, Netherlands
    • Canisius Wilhelmina Ziekenhuis
  • Sittard-Geleen, Netherlands, 6162 BG
    • Academic MS Center Limburg, Orbis Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Female
• Relapsing Remitting MS
• At start of study > 6 weeks in clinical remission of disease
• Age > 18 years.
• Premenopausal
• Treated with either no immune-modulating treatment, or the currently registered MS modulating treatments: Interferon beta 1a (Rebif®), Interferon Beta 1b (Betaferon® or Avonex®), Glatiramer Acetate (Copaxone®), dimethylfumarate (Tecfidera®), teriflunomide (Aubagio®)) or fingolimod (Gilenya®).

Exclusion Criteria:

• Any contraindication to vitamin D according to Summary of Product Characteristics: Hypercalcaemia, hypervitaminosis D, nephrolithiasis, diseases or conditions resulting in hypercalcaemia and/or hypercalciuria (incl. primary hyperparathyroidism), severe renal impairment .
• Use of dexamethasone or other systemic glucocorticosteroids <2 months prior to first study visit
• Supplementation of >=1000 IU/d (25µg) vitamin D2 or D3
• Medical history of disturbed vitamin D/ calcium metabolism other than low intake
• Present clinical (major)depression
• Present treatment with anti-depressants, benzodiazepines, or neuroleptics.
• Treatment with high-dose dexamethasone for MS exacerbation during study.
• Pregnancy or the intention to become pregnant during the study period.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cholecalciferol; Patients receive 1dd 100ug vitamin D3 (drops) for 16 weeks	Drug: Cholecalciferol; Vitamin D3 solution; Other Names: Vigantol Oil
Placebo Comparator: Placebo comparator; placebo drops during 16 weeks	Other: Placebo comparator; Placebo comparator

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The area under the curve (AUC) of the cortisol day curve	This number is constructed by combining the saliva cortisol levels at awakening, 11:00, 15:00, 20:00, and 22:00 hours (5 time-points).	At baseline and after 16 weeks of supplementation.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The slope of the cortisol day-curve	The slope of the day-curve is the slope of the decrease of saliva cortisol measured throughout the cortisol day curve	At baseline and after 16 weeks of supplementation
The cortisol awakening response	The awakening response is described by the rise in saliva cortisol from awakening to 60 minutes after awakening with respectively measurements at awakening, 15 minutes, 30 minutes, 45 minutes and 60 minutes (5 time-points).	At baseline and after 16 weeks of supplementation
Clinical outcomes on depression	The clinical outcomes on depression will be measured by the depression sub-score of HADS and the FSSS fatigue score.	At baseline and after 16 weeks of supplementation
Efficacy of supplementation	To measure efficacy 25(OH)D levels will be measured.	At baseline and after 16 weeks of supplementation. Side effects will also be checked at 8 weeks of supplementation.
Side effects	Side effects will be measured after 8 and 16 weeks of treatment. Serum levels of calcium, albumin and creatinine will be determined, as well as calcium and creatinine levels in urine.	At baseline, after 8 and after 16 weeks

Collaborators and Investigators

• Sponsor: Academic MS Center Limburg
• Investigators: Principal Investigator: Raymond Hupperts, MD, PhD, Academic MS Center Limburg, Orbis MC

Publications and helpful links

General Publications

• Rolf L, Damoiseaux J, Huitinga I, Kimenai D, van den Ouweland J, Hupperts R, Smolders J. Stress-Axis Regulation by Vitamin D3 in Multiple Sclerosis. Front Neurol. 2018 Apr 26;9:263. doi: 10.3389/fneur.2018.00263. eCollection 2018.

Study record dates

Study Major Dates

• Study Start: October 13, 2014
• Primary Completion (Actual): November 7, 2016
• Study Completion (Actual): November 7, 2016

Study Registration Dates

• First Submitted: March 21, 2014
• First Submitted That Met QC Criteria: March 24, 2014
• First Posted (Estimate): March 26, 2014

Study Record Updates

• Last Update Posted (Estimate): January 25, 2017
• Last Update Submitted That Met QC Criteria: January 24, 2017
• Last Verified: January 1, 2017

More Information

Terms related to this study

• Keywords: Multiple sclerosis, vitamin D, HPA-axis, cortisol
• Additional Relevant MeSH Terms: Pathologic Processes; Nervous System Diseases; Immune System Diseases; Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Demyelinating Diseases; Autoimmune Diseases; Multiple Sclerosis; Sclerosis; Physiological Effects of Drugs; Micronutrients; Vitamins; Bone Density Conservation Agents; Calcium-Regulating Hormones and Agents; Vitamin D; Cholecalciferol
• Other Study ID Numbers: EMR200109_635; 2014-000728-97 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED